HOUSTON , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, announced today that its chief executive officer, David Arthur , will present at

HOUSTON , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19 th at 12pm Eastern Time .

Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020 HOUSTON , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression,

Presentation Will Provide Overview of Ongoing Clinical Trial of Salarius’ Lead Drug Candidate, Seclidemstat, in Ewing Sarcoma HOUSTON , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer,

HOUSTON , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals , Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its corporate and financial results for the quarter ended September 30, 2019.

Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over a 30-Month Span Extending into 2022 HOUSTON , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting

HOUSTON , Oct. 14, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming investor conferences. Management will provide an overview of Salarius’ business

Salarius Targeting Key Safety and Efficacy Data Milestones in 2020   HOUSTON , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.  (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering Cancer Center

Fourth Level Dosing Cohorts Now Proceeding Following Safety Review Committee Clearance   HOUSTON , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that the Safety Review

Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer HOUSTON , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the